Photocure ASA
PHO.OLNext catalyst
Cysview
Bladder Cancer
Get an email about PHO.OL's next catalysts
Track Photocure ASA (PHO.OL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 0 past
Cysview Phase 3 Est. Readout
Estimated primary completion for Cysview trial (NCT06525571) in Bladder Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Hexvix
Bladder Cancer
clobetasol propionate
Genital Lichen Planus
Hexaminolevulinate Hydrochloride
Bladder Cancer
hexaminolevulinate
Bladder Cancer
Cysview
Bladder Cancer
HAL with illumination
Cervical Intraepithelial Neoplasia
Methyl aminolevulinate (MAL) PDT
Acne Vulgaris
methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Cervical Dysplasia
Visonac left on the skin for 24 hours in facial area one
Acne Vulgaris
Visonac left on the skin 24 hours in facial area two
Acne Vulgaris
Visonac wiped off after one hour
Acne Vulgaris
Visonac PDT
Acne Vulgaris
Visonac PDT (MAL PDT)
Acne Vulgaris
Area cleaned with Ethyl alcohol solution
Acne Vulgaris
MAL
Acne
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Hexvix | Phase 3 | Bladder Cancer | - | - |
clobetasol propionate | Phase 3 | Genital Lichen Planus | - | - |
Hexaminolevulinate Hydrochloride | Phase 3 | Bladder Cancer | - | - |
hexaminolevulinate | Phase 3 | Bladder Cancer | - | - |
Cysview | Phase 3 | Bladder Cancer | - | - |
HAL with illumination | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
Methyl aminolevulinate (MAL) PDT | Phase 2 | Acne Vulgaris | - | - |
methyl aminolevulinate (MAL) and hexaminolevulinate (HAL) | Phase 2 | Cervical Dysplasia | - | - |
Visonac left on the skin for 24 hours in facial area one | Phase 2 | Acne Vulgaris | - | - |
Visonac left on the skin 24 hours in facial area two | Phase 2 | Acne Vulgaris | - | - |
Visonac wiped off after one hour | Phase 2 | Acne Vulgaris | - | - |
Visonac PDT | Phase 2 | Acne Vulgaris | - | - |
Visonac PDT (MAL PDT) | Phase 2 | Acne Vulgaris | - | - |
Area cleaned with Ethyl alcohol solution | Phase 2 | Acne Vulgaris | - | - |
MAL | Phase 2 | Acne | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Photocure ASA's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Photocure ASA's (PHO.OL) pipeline across Phase 3, Phase 2. Its lead program is Cysview (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Photocure ASA's next FDA catalyst?→
Photocure ASA's (PHO.OL) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHO.OL biotech catalysts?→
Add PHO.OL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Photocure ASA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
